Manufacturing

We believe that no cancer patient should go without the safe and effective treatment they need.

Arrow Down Icon

Quality

Reliability

Innovation

Virus manufacturing for oncolytic virotherapy


The registration and commercialization for new medication is a highly demanding and technical challenge, considering the development of a reliable and sustainable manufacturing process for production of safe and effective products in compliance with global regulatory requirements.

Rigvir Group has restructured according to GMP guidelines (Good Manufacturing Practice regulations), establishing its center of premium biotechnological manufacturing with increased scale, capacity, diversification of R&D capabilities and exceptional know-how to produce the high-quality oncolytic ECHO-7 virus.





Reliable production of consistent oncotropic, non-pathogenic virus.

Disease – specific oncolytic virotherapy development.